May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Visudyne Anti-VEGF Combination Therapy (VACT): A Multicentred, Retrospective Clinical Practice Review of Combination Therapy in AMD
Author Affiliations & Notes
  • P. L. Hooper
    Ivey Eye Institute, University of Western Ontario, London, Ontario, Canada
  • T. G. Sheidow
    Ivey Eye Institute, University of Western Ontario, London, Ontario, Canada
  • VACT Study Group
    Ivey Eye Institute, University of Western Ontario, London, Ontario, Canada
  • Footnotes
    Commercial Relationships P.L. Hooper, Novartis Canada, R; T.G. Sheidow, Novartis Canada, R.
  • Footnotes
    Support The VACT database is supported and maintained by Novartis Ophthalmics Canada
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4537. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. L. Hooper, T. G. Sheidow, VACT Study Group; Visudyne Anti-VEGF Combination Therapy (VACT): A Multicentred, Retrospective Clinical Practice Review of Combination Therapy in AMD. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4537.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: The Visudyne Anti-VEGF Combination Therapy (VACT) data collection is designed to collect retrospective clinical practice data on combination therapy at baseline with an angio-occlusive agent (Visudyne) and an anti-VEGF agent (Avastin).

Methods:: Retrospective data from 10 Canadian centres was collected on patients receiving PDT within 14 days of intravitreal Avastin.

Results:: To date, a total of 206 patients have been included with 163 patients completing >4 months of follow-up. All lesion subtypes were included in the study. Mean visual acuity at baseline was 20/250 with a GLD of 2898 microns with a mean central retinal thickness of 251 microns. 43% of patients were treatment naïve.On average, at 4 months, visual acuity improved 7.8 letters from baseline with 84% of patients avoiding moderate visual loss. A total of 46% of patients gained 5 letters or more, with 33% gaining 15 or more letters from baseline.A planned continuation of the database registry will be presented with follow up data.

Conclusions:: Combination therapy with PDT and Avastin appears to offer excellent visual outcome with respect to avoidance of moderate visual loss and potential for visual gain. Additional follow up will help to assess the overall benefit of this mode of therapy and its ability to reduce the number of patient treatments while maintaining vision.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: outcomes/complications • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×